CHANDAN Chandan Healthca Q4 FY26 results (Jan–Mar 2026) and concall
Chandan Healthcare Limited reported a strong Q4 and full year FY26, with revenue growing over 20% and EBITDA expanding by 31% YoY for the full year. The company achieved significant milestones in geographical expansion, including pan-India presence and securing large PPP projects. Management outlined an aggressive expansion strategy focusing on comprehensive diagnostic centers, franchise scaling, and new specialized services like PET scans and a genome lab, while aiming to maintain EBITDA margins between 30-35% in the medium term.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 20.6%, net profit down 17.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 110 | 55 | 63 | 68 | 68 −38% | 65 +19% | 76 +21% |
| EBITDA | 20 | 9 | 10 | 14 | 14 −29% | 12 +33% | 11 +12% |
| Net profit | 11 | 4 | 6 | 6 | 8 −29% | 5 +8% | 5 −18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
